EA201891340A1 - Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек - Google Patents

Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек

Info

Publication number
EA201891340A1
EA201891340A1 EA201891340A EA201891340A EA201891340A1 EA 201891340 A1 EA201891340 A1 EA 201891340A1 EA 201891340 A EA201891340 A EA 201891340A EA 201891340 A EA201891340 A EA 201891340A EA 201891340 A1 EA201891340 A1 EA 201891340A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
deoxy
combination
fukoza
fluor
Prior art date
Application number
EA201891340A
Other languages
English (en)
Russian (ru)
Inventor
Шира Гардай
Чэ-Леунг Ло
Питер Сентер
Николь Окили
Джессика Филд
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Publication of EA201891340A1 publication Critical patent/EA201891340A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201891340A 2015-12-04 2016-12-02 Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек EA201891340A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US201662321857P 2016-04-13 2016-04-13
PCT/US2016/064783 WO2017096274A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
EA201891340A1 true EA201891340A1 (ru) 2018-11-30

Family

ID=58797961

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891340A EA201891340A1 (ru) 2015-12-04 2016-12-02 Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек

Country Status (13)

Country Link
US (1) US20180353524A1 (https=)
EP (1) EP3383404A4 (https=)
JP (1) JP6906520B2 (https=)
KR (1) KR20180086233A (https=)
CN (1) CN108289903B (https=)
AU (1) AU2016362993A1 (https=)
BR (1) BR112018011261A2 (https=)
CA (1) CA3005997A1 (https=)
EA (1) EA201891340A1 (https=)
IL (1) IL259479B (https=)
MX (1) MX385283B (https=)
SG (2) SG10202005298RA (https=)
WO (1) WO2017096274A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2608796T3 (en) 2010-08-05 2019-03-18 Seattle Genetics Inc Inhibition of protein fucosylation in vivo using fucose analogues
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
JP7245177B2 (ja) * 2017-06-07 2023-03-23 シージェン インコーポレイテッド 低減した表面フコシル化を有するｔ細胞、及びそれを作製及び使用する方法
WO2019075449A1 (en) * 2017-10-13 2019-04-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. FUCOSYLATION AND IMMUNOSURVEILLANCE OF MELANOMA
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
SG11202106481SA (en) * 2018-12-19 2021-07-29 Seagen Inc Controlled fucosylation of antibodies
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN111973749B (zh) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 一种抗肿瘤免疫治疗的药物组合物
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (zh) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于特定型三阴乳腺癌免疫治疗的组合物
WO2022236017A1 (en) * 2021-05-06 2022-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
CN115466297B (zh) * 2022-08-25 2023-07-07 青岛农业大学 L-岩藻糖的应用以及动物饲料
WO2024077106A2 (en) * 2022-10-04 2024-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2608796T3 (en) * 2010-08-05 2019-03-18 Seattle Genetics Inc Inhibition of protein fucosylation in vivo using fucose analogues
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물

Also Published As

Publication number Publication date
BR112018011261A2 (pt) 2018-11-21
EP3383404A4 (en) 2019-07-31
EP3383404A1 (en) 2018-10-10
IL259479B (en) 2022-03-01
WO2017096274A1 (en) 2017-06-08
SG11201804263PA (en) 2018-06-28
JP2019501145A (ja) 2019-01-17
US20180353524A1 (en) 2018-12-13
JP6906520B2 (ja) 2021-07-21
CN108289903B (zh) 2021-08-03
MX385283B (es) 2025-03-18
SG10202005298RA (en) 2020-07-29
AU2016362993A1 (en) 2018-07-12
MX2018006674A (es) 2018-11-09
KR20180086233A (ko) 2018-07-30
CN108289903A (zh) 2018-07-17
CA3005997A1 (en) 2017-06-08
IL259479A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
IL254720A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201591509A1 (ru) Ингибиторы cdc7
MX2017013802A (es) Métodos para tratar el cáncer.
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
PH12017500881B1 (en) Aurora a kinase inhibitor
GB2541571A (en) Pharmaceutical compositions
KR20180084772A (ko) 암 치료를 위한 조합 치료법
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
EA201792227A1 (ru) Лечение рака легких ингибиторами глутаминазы
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
EA201991818A1 (ru) Лечение рака
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2016009663A (es) Derivados de icariina.
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX390320B (es) Farmaco de combinacion.
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
EA201692534A1 (ru) Способы лечения гипотонии
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.